MGC018 targets B7-H3 on tumor cells; after internalization, the duocarmycin payload is released and alkylates adenine N3 in the DNA minor groove, causing DNA damage and death. The DNA minor groove is the payload’s intracellular binding site, not the selective antigen used for targeting.